Clinical safety of biosimilar recombinant human erythropoietins.
about
Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review.Biosimilars: Implications for health-system pharmacists.Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.The evolving role of biosimilars in haematology-oncology: a practical perspective.Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Pharmacovigilance in practice: erythropoiesis-stimulating agents.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.Biosimilars in 3D: definition, development and differentiationHX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors.Development and 10-year history of a biosimilar: the example of Binocrit®.
P2860
Q30911529-32198A11-AB99-458D-81AA-9689A785C8F2Q34372394-8BE1C3AB-AF2A-4E9F-8057-02D746CBFCB2Q35162053-15DE6F05-C8D3-4252-9FBF-4A19B6B2631BQ36291259-507F205E-4BC7-4F1B-9B90-C8E74D8D83C1Q37474361-D8409741-AE21-4D99-850F-EB9C4E030D23Q37632227-DB608B49-C5FA-404D-9AB9-402A279EA20FQ38075798-3B20E437-F6C4-413E-BC40-BF7651ECAABAQ38082542-2BDD09D6-DCC9-459F-9F58-35AC64CC174BQ38217083-CB4320B1-E6B6-46BC-960F-BCADBA66ADBEQ38556990-8F744352-55B3-44C1-92FB-FF6EC1F8A076Q38763700-6B4FFECD-797A-4986-AE73-677DE63D7A0EQ39141802-21A27DD0-C272-4227-B8FD-04D602990058Q39293869-DAB1F00F-9FF6-44AA-BC18-0D2E3295C912Q41961612-0C1CC5A5-AE6A-4C86-80D2-9ECAAC8D9CE8Q47094186-C1010920-5A8A-4827-9293-5E063B096BA1Q48080576-55E32EF9-8CDC-4E3E-98D7-3371C3F85A94Q51197806-C596570D-ACC3-4613-8D08-C5CFA349D993Q55177169-5164C019-2DDE-4EAB-8F97-772D464EA02D
P2860
Clinical safety of biosimilar recombinant human erythropoietins.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical safety of biosimilar recombinant human erythropoietins.
@en
type
label
Clinical safety of biosimilar recombinant human erythropoietins.
@en
prefLabel
Clinical safety of biosimilar recombinant human erythropoietins.
@en
P2860
P1476
Clinical safety of biosimilar recombinant human erythropoietins.
@en
P2093
Ivo Abraham
Karen MacDonald
P2860
P304
P356
10.1517/14740338.2012.712681
P407
P577
2012-08-13T00:00:00Z